This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated. View Details
Description: This MJD2 monoclonal antibody reacts with HER-2, the product of the ErbB2 gene and a member of the human epidermal growth factor receptor (EGFR) family. HER-2 is a 185 kDa transmembrane receptor with an extracellular binding domain and an intracellular tyrosine kinase domain. Activation of HER-2 occurs following formation of homodimers or heterodimers with ligand-bound EGFR family members, HER3 or HER4. Overexpression of HER-2 results in auto-phosphorylation and increased proliferation and invasiveness and is associated with subsets of multiple cancer types such as breast, ovarian, cervical, uterine, and gastric. The use of HER-2 targeted agents has been used extensively to treat HER-2-positive breast cancer, but a recent study found that these agents can also block the proliferation of breast cancer stem cells found in HER-2-negative patients and suggests the importance of HER-2 as a target for multiple types of breast cancer. The MJD2 antibody recognizes the extracellular domain of HER-2 but at an epitope distinct from that recognized by the 4D5 (Herceptin) and SP3 monoclonal antibodies.
Applications Reported: This MJD2 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, microscopy, and immunocytochemistry.
Applications Tested: This MJD2 antibody has been tested by immunhistochemistry of formalin-fixed paraffin embedded human tissue using low or high pH antigen retrieval and can be used at less than or equal to 5 µg/mL. This MJD2 antibody has been tested by immunocytochemistry of methanol-fixed and permeabilized human BT474 cells and can be used at less than or equal to 5 µg/mL. This MJD2 antibody has been tested by western blot analysis of reduced human BT474 cell lysate and can be used at less than or equal to 5 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: c-erb B2/neu protein; CD antigen CD340; CD340; erb-b2; erbb 2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; her 2; herstatin; human epidermal growth factor receptor 2; metas; Metastatic lymph node gene 19 protein; MLN 19; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; p185erbB2; phospho ErbB2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; Receptor tyrosine-protein kinase erbB-2; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Gene Aliases: CD340; ERBB2; HER-2; HER-2/neu; HER2; MLN 19; MLN19; NEU; NGL; TKR1
UniProt ID: (Human) P04626
Entrez Gene ID: (Human) 2064